Cvs Health Corp. (CVS) Holder Peloton Wealth Strategists Has Decreased Position by $556,200 as Share Value Declined; As Abbott Labs (ABT) Market Value Rose, Partner Fund Management LP Has Lowered Its Position by $3.90 Million

May 26, 2018 - By Michael Collier

CVS Health Corporation (NYSE:CVS) Logo

Christopher Medlock James decreased its stake in Abbott Labs (ABT) by 3.8% based on its latest 2017Q4 regulatory filing with the SEC. Partner Fund Management Lp sold 68,426 shares as the company’s stock rose 5.88% while stock markets declined. The hedge fund run by Christopher Medlock James held 1.73M shares of the major pharmaceuticals company at the end of 2017Q4, valued at $98.88 million, down from 1.80 million at the end of the previous reported quarter. Partner Fund Management Lp who had been investing in Abbott Labs for a number of months, seems to be less bullish one the $109.35 billion market cap company. The stock decreased 0.22% or $0.14 during the last trading session, reaching $62.37. About 3.84 million shares traded. Abbott Laboratories (NYSE:ABT) has risen 34.85% since May 26, 2017 and is uptrending. It has outperformed by 23.30% the S&P500.

Peloton Wealth Strategists decreased its stake in Cvs Health Corp. (CVS) by 28.37% based on its latest 2017Q4 regulatory filing with the SEC. Peloton Wealth Strategists sold 7,725 shares as the company’s stock declined 17.45% with the market. The institutional investor held 19,500 shares of the medical and nursing services company at the end of 2017Q4, valued at $1.41 million, down from 27,225 at the end of the previous reported quarter. Peloton Wealth Strategists who had been investing in Cvs Health Corp. for a number of months, seems to be less bullish one the $67.13 billion market cap company. The stock increased 1.40% or $0.91 during the last trading session, reaching $66.03. About 5.56M shares traded. CVS Health Corporation (NYSE:CVS) has declined 22.81% since May 26, 2017 and is downtrending. It has underperformed by 34.36% the S&P500.

More notable recent CVS Health Corporation (NYSE:CVS) news were published by: Prnewswire.com which released: “CVS Health Statement on Trump Administration Initiative to Reduce Drug Costs” on May 11, 2018, also Seekingalpha.com with their article: “Trade Mistake 3: CVS Boredom Trade” published on May 09, 2018, Seekingalpha.com published: “CVS: Going Long, And Understanding The Aetna Deal” on April 30, 2018. More interesting news about CVS Health Corporation (NYSE:CVS) were released by: 247Wallst.com and their article: “Alibaba, CVS, Tesla and Other Earnings to Watch For This Week” published on April 29, 2018 as well as Seekingalpha.com‘s news article titled: “We Are Playing The CVS Hand” with publication date: May 11, 2018.

Since February 16, 2018, it had 2 insider purchases, and 1 insider sale for $713,454 activity. On Friday, May 4 the insider DORMAN DAVID W bought $1.51M. The insider Foulkes Helena sold 19,965 shares worth $1.42 million.

Peloton Wealth Strategists, which manages about $175.56M and $134.54 million US Long portfolio, upped its stake in Allergan Inc. by 3,700 shares to 14,185 shares, valued at $2.32 million in 2017Q4, according to the filing.

Among 26 analysts covering CVS Health (NYSE:CVS), 19 have Buy rating, 0 Sell and 7 Hold. Therefore 73% are positive. CVS Health had 77 analyst reports since July 22, 2015 according to SRatingsIntel. Mizuho maintained CVS Health Corporation (NYSE:CVS) rating on Thursday, June 23. Mizuho has “Buy” rating and $108 target. The stock of CVS Health Corporation (NYSE:CVS) has “Overweight” rating given on Friday, December 18 by Barclays Capital. The rating was maintained by Tigress Financial on Tuesday, December 26 with “Buy”. The rating was maintained by Jefferies on Wednesday, August 16 with “Hold”. The stock of CVS Health Corporation (NYSE:CVS) earned “Buy” rating by Needham on Tuesday, January 2. The company was initiated on Thursday, October 6 by UBS. The stock of CVS Health Corporation (NYSE:CVS) has “Buy” rating given on Monday, December 4 by RBC Capital Markets. The stock of CVS Health Corporation (NYSE:CVS) earned “Overweight” rating by Morgan Stanley on Friday, January 5. Oppenheimer maintained it with “Outperform” rating and $117 target in Thursday, December 17 report. The rating was maintained by Deutsche Bank with “Hold” on Wednesday, July 22.

Analysts await CVS Health Corporation (NYSE:CVS) to report earnings on August, 14. They expect $1.61 EPS, up 21.05% or $0.28 from last year’s $1.33 per share. CVS’s profit will be $1.64 billion for 10.25 P/E if the $1.61 EPS becomes a reality. After $1.48 actual EPS reported by CVS Health Corporation for the previous quarter, Wall Street now forecasts 8.78% EPS growth.

Investors sentiment decreased to 0.72 in Q4 2017. Its down 0.16, from 0.88 in 2017Q3. It is negative, as 115 investors sold CVS shares while 600 reduced holdings. 134 funds opened positions while 380 raised stakes. 815.59 million shares or 1.76% more from 801.45 million shares in 2017Q3 were reported. Cornercap Invest Counsel Inc invested in 0.5% or 50,067 shares. Creative Planning holds 0.03% or 96,576 shares in its portfolio. Azimuth Cap Lc has 50,541 shares. 36,027 are held by Meiji Yasuda Asset Com. 17,270 were accumulated by First Natl Trust. Dowling Yahnke Lc reported 0.42% stake. Middleton Communications Inc Ma stated it has 0.36% in CVS Health Corporation (NYSE:CVS). 90 were reported by Goodman Financial. Cadence Bankshares Na invested in 0.34% or 12,697 shares. First Wilshire Secs Inc has invested 0.09% in CVS Health Corporation (NYSE:CVS). Tennessee-based Td Capital Mgmt Ltd Liability Co has invested 0.03% in CVS Health Corporation (NYSE:CVS). Rmb Management Lc reported 0.02% stake. 174,977 are held by Parthenon Limited Liability. The Massachusetts-based Colony Gp Ltd Liability Corporation has invested 0.78% in CVS Health Corporation (NYSE:CVS). Sg Americas Securities Ltd Liability Company has invested 0.14% of its portfolio in CVS Health Corporation (NYSE:CVS).

Analysts await Abbott Laboratories (NYSE:ABT) to report earnings on July, 19. They expect $0.71 EPS, up 14.52% or $0.09 from last year’s $0.62 per share. ABT’s profit will be $1.24 billion for 21.96 P/E if the $0.71 EPS becomes a reality. After $0.59 actual EPS reported by Abbott Laboratories for the previous quarter, Wall Street now forecasts 20.34% EPS growth.

Among 25 analysts covering Abbott Laboratories (NYSE:ABT), 18 have Buy rating, 0 Sell and 7 Hold. Therefore 72% are positive. Abbott Laboratories had 107 analyst reports since July 24, 2015 according to SRatingsIntel. The stock has “Market Perform” rating by BMO Capital Markets on Tuesday, March 14. Jefferies maintained Abbott Laboratories (NYSE:ABT) on Wednesday, April 18 with “Buy” rating. The firm has “Buy” rating given on Saturday, August 29 by BTIG Research. The stock has “Outperform” rating by BMO Capital Markets on Tuesday, December 12. BMO Capital Markets maintained Abbott Laboratories (NYSE:ABT) rating on Thursday, October 19. BMO Capital Markets has “Market Perform” rating and $5 target. On Tuesday, April 24 the stock rating was maintained by Citigroup with “Neutral”. JP Morgan maintained Abbott Laboratories (NYSE:ABT) on Thursday, January 25 with “Overweight” rating. The firm has “Market Perform” rating by William Blair given on Friday, January 29. The rating was maintained by RBC Capital Markets with “Buy” on Thursday, October 19. RBC Capital Markets maintained the stock with “Outperform” rating in Wednesday, March 1 report.

Since December 14, 2017, it had 1 buy, and 21 sales for $23.88 million activity. $1.56 million worth of Abbott Laboratories (NYSE:ABT) was sold by Salvadori Daniel Gesua Sive. On Wednesday, February 28 the insider BIRD ROGER sold $96,728. $125,909 worth of Abbott Laboratories (NYSE:ABT) was sold by Bracken Sharon J. $84,344 worth of Abbott Laboratories (NYSE:ABT) was sold by MANNING JOSEPH J on Wednesday, February 28. Contreras Jaime had sold 6,284 shares worth $375,381 on Wednesday, February 28. 11,106 shares were sold by Fussell Stephen R, worth $667,804 on Wednesday, February 28.

Investors sentiment increased to 0.91 in Q4 2017. Its up 0.04, from 0.87 in 2017Q3. It is positive, as 52 investors sold ABT shares while 558 reduced holdings. 123 funds opened positions while 430 raised stakes. 1.22 billion shares or 0.64% more from 1.21 billion shares in 2017Q3 were reported. Papp L Roy And Assocs reported 0.1% of its portfolio in Abbott Laboratories (NYSE:ABT). Kcm Limited Liability reported 207,651 shares. Moreover, Regal Invest Advsr Ltd Liability Corporation has 0.07% invested in Abbott Laboratories (NYSE:ABT) for 5,507 shares. Comerica Natl Bank invested in 1.15M shares. Martin & Tn reported 56,390 shares or 1.02% of all its holdings. Moreover, Lau Associate Ltd Liability has 0.58% invested in Abbott Laboratories (NYSE:ABT) for 13,047 shares. Connors Investor Serv reported 206,299 shares or 1.69% of all its holdings. Huntington Savings Bank invested 0.56% in Abbott Laboratories (NYSE:ABT). Koshinski Asset Mngmt holds 0.48% of its portfolio in Abbott Laboratories (NYSE:ABT) for 33,472 shares. Nomura invested in 0.04% or 401,512 shares. Bartlett And Limited Liability Co has 879,015 shares. Bnp Paribas Asset Mngmt Holdings Sa reported 786,054 shares. Keating Inv Counselors reported 0.14% stake. Of Vermont invested 0.98% in Abbott Laboratories (NYSE:ABT). Andra Ap stated it has 219,500 shares.

More news for Abbott Laboratories (NYSE:ABT) were recently published by: Bizjournals.com, which released: “Federal court hands down $500K judgment against St. Pete man charged in stock scheme” on May 25, 2018. Streetinsider.com‘s article titled: “Stifel Sees Minimal Impact from Abbott Labs (ABT) HeartMate III ‘Dear Doc Letter'” and published on May 23, 2018 is yet another important article.

Partner Fund Management Lp, which manages about $4.22B US Long portfolio, upped its stake in Molina Healthcare Inc (NYSE:MOH) by 684,477 shares to 1.17M shares, valued at $90.08 million in 2017Q4, according to the filing. It also increased its holding in Coupa Software Inc by 340,788 shares in the quarter, for a total of 342,725 shares, and has risen its stake in Penumbra Inc.

CVS Health Corporation (NYSE:CVS) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:


Recent Market News

>